Immunitybio, INC

ImmunityBio announced record Q2 2026 net product revenue of $50.7 million, up 92% year-over-year, alongside significant progress in its clinical pipeline and regulatory milestones.

ImmunityBio announced that the UAE has granted marketing authorization for ANKTIVA in two indications: BCG-unresponsive bladder cancer and metastatic non-small cell lung cancer.

ImmunityBio, Inc. successfully held its 2026 Annual Meeting of Stockholders, confirming the re-election of all nine director nominees and the ratification of its independent auditor.

ImmunityBio has entered an exclusive agreement with Japan BCG Laboratory to develop and commercialize the Tokyo-172 BCG strain in the U.S. to address chronic supply shortages.

ImmunityBio announced record Q1 2026 results with net product revenue soaring to $44.2 million, a nearly 2.7x increase year-over-year, driven by strong ANKTIVA sales and expanding market approvals.

ImmunityBio announced preliminary Q1 2026 net product revenue of approximately $44.2 million, a 168% increase year-over-year, driven by ANKTIVA adoption.

ImmunityBio, Inc. reported Q2 2026 results showing significant revenue growth but also substantial net losses and increased liabilities, alongside ongoing legal matters.

ImmunityBio, Inc. has filed its 2025 Equity Incentive Plan, detailing provisions for stock options, restricted stock units, and performance awards to attract and retain key personnel.

ImmunityBio reports significant product revenue growth driven by ANKTIVA sales, strengthens cash position through equity offerings, and advances its clinical pipeline despite ongoing net losses and regulatory challenges.

ImmunityBio reports significant Q2 2025 revenue growth driven by ANKTIVA sales and secures UK marketing authorization, while navigating ongoing regulatory and financial challenges.

ImmunityBio's Q1 2025 shows increased ANKTIVA sales but ongoing losses and a mixed regulatory outlook.

ImmunityBio reports its Q3 2024 results, highlighting the start of ANKTIVA sales and ongoing clinical development.

ImmunityBio reports significant revenue growth and multiple international approvals for its lead immunotherapy ANKTIVA, while navigating substantial operating losses, ongoing legal disputes, and the need for additional financing.

ImmunityBio's 2024 10-K highlights the commercialization of ANKTIVA, strategic collaborations, and the advancement of its immunotherapy pipeline to address cancers and infectious diseases.

ImmunityBio's annual 10-K filing details its financial status, clinical pipeline, and strategic vision, emphasizing its focus on next-generation immunoand cellular therapies.

Cheryl Cohen, a Director at ImmunityBio, Inc., reported transactions involving the sale of company stock.

ImmunityBio, Inc. Director Christobel Selecky reported transactions involving the acquisition and sale of common stock, executed under a pre-arranged Rule 10b5-1 trading plan.

ImmunityBio Director Christobel Selecky executed a series of stock option exercises and sales under a pre-arranged Rule 10b5-1 trading plan.

ImmunityBio Director Barry J. Simon sold 25,000 shares of common stock for approximately $7.88 per share, executed under a pre-arranged Rule 10b5-1 trading plan.

Director Michael D. Blaszyk was granted 65,600 stock options in ImmunityBio, Inc. as part of the company's 2025 Equity Incentive Plan.

Director Bruce Wendel was granted 65,600 stock options in ImmunityBio, Inc. under the company's 2025 Equity Incentive Plan.

ImmunityBio, Inc. has increased its authorized common stock to 1.65 billion shares to secure future funding and meet existing commitments.

ImmunityBio, Inc. is holding its 2025 Annual Meeting on June 18, 2025, and has released proxy materials for stockholders to review and vote on key proposals.

ImmunityBio announces its 2025 annual meeting of stockholders to be held virtually on June 18, 2025, to vote on director elections, an equity incentive plan, and auditor ratification.

ImmunityBio, Inc. is holding its annual meeting on June 11, 2024, and is soliciting stockholder votes on director elections, an equity incentive plan amendment, executive compensation, and auditor ratification.

ImmunityBio's upcoming annual meeting on June 11, 2024, will include proposals for director elections, an equity incentive plan amendment, executive compensation approval, and auditor ratification.

An amended Schedule 13D filing for ImmunityBio, Inc. details substantial beneficial ownership by Patrick Soon-Shiong and affiliated entities, collectively holding a significant portion of the company's common stock.

Dr. Patrick Soon-Shiong and affiliated entities have increased their beneficial ownership in ImmunityBio, Inc. to 66.3% of outstanding common stock.

An amendment to Schedule 13D details the beneficial ownership of ImmunityBio, Inc. common stock by Patrick Soon-Shiong and affiliated entities, with Dr. Soon-Shiong's aggregate stake reaching 68.9%.